Amivantamab and Lazertinib in Patients with EGFR+ NSCLC – 2022 Program: Targeted Therapies Forum

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Angel Qin looks at the Chrysalis-2 Trial, which studied the combination of Amivantamab and Lazertinib for EGFR+ NSCLC Patients with Progression on Osimertinib and platinum-based chemo.

We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech

For more, please visit http://cancerGRACE.org/.
To join the conversation, visit https://cancergrace.org/forum.